yttrium radioisotopes has been researched along with Pancreatic Neoplasms in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (12.70) | 18.2507 |
| 2000's | 19 (30.16) | 29.6817 |
| 2010's | 30 (47.62) | 24.3611 |
| 2020's | 6 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrens, M; Bauer, S; Fendler, WP; Ferdinandus, J; Fragoso Costa, P; Hamacher, R; Herrmann, K; Kessler, L; Kostbade, K; Lippert, M; Lueckerath, K; Mavroeidi, IA; Pabst, KM; Rischpler, C; Schuler, M; Siveke, JT; Umutlu, L; Weber, M | 1 |
| Durma, AD; Jóźwik-Plebanek, K; Kamiński, G; Kołodziej, M; Saracyn, M | 1 |
| Bai, HX; Dagli, M; Habibollahi, P; Sanampudi, S; Soulen, MC | 1 |
| Ćwikła, JB; Kolasińska-Ćwikła, A; Maciejkiewicz, KM; Łowczak, A | 1 |
| Higashi, T; Koizumi, M; Kurosawa, G; Kurosawa, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y | 1 |
| Aung, W; Furukawa, T; Kouda, K; Kurosawa, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y | 1 |
| Alexander, HC; Bartlett, ASJR; Chu, MJJ; Han, CH; Holden, AH; Nguyen, CH; Tarr, GP; Thomas, RH | 1 |
| Aluicio-Sarduy, E; Cai, W; Ehlerding, EB; Engle, JW; Ferreira, CA; Jiang, D; Ni, D; Rosenkrans, ZT; Sun, T | 1 |
| Choi, J; El-Haddad, G; Frakes, J; Kayaleh, R; Kis, B; Krzyston, H; Naziri, J; Parikh, N; Rishi, A; Sweeney, J | 1 |
| Akhter, N; Brower, J; Frantz, S; Kim, AY | 1 |
| Colquhoun, SD; Friedman, ML; Kim, AS; Nissen, NN; Ozao-Choy, J; Wachsman, A; Wolin, EM; Yu, R | 1 |
| Caballero-Díaz, C; Camps Herrero, C; Civera-Andrés, M; Ferrer-García, JC; Iranzo González-Cruz, V; Merchante-Alfaro, A; Morillas-Ariño, C; Navas-DeSolís, S; Sánchez-Juan, C | 1 |
| Banks, M; Cuthbertson, DJ; Gilbert, TM; Maltby, P; McKane, G; Palmer, DH; Poston, G; Pritchard, DM; Vinjamuri, S; Vora, J; Weissman, H | 1 |
| Cacciari, G; Campana, D; Capurso, G; Delle Fave, G; Falconi, M; Nori, F; Panzuto, F; Partelli, S; Tamburrino, D; Tomassetti, P | 1 |
| Bartenstein, P; Boeck, S; Haas, M; Haug, AR; Heinemann, V; Hoffmann, RT; Jakobs, TF; Laubender, RP; Michl, M; Paprottka, P | 1 |
| John, PK; Saif, MW | 1 |
| Bozkaya, H; Çınar, C; Güneyli, S; Korkmaz, M; Oran, İ; Parıldar, M; Şanal, B | 1 |
| Agostini, M; Amadori, S; Bartolini, N; Bartolomei, M; Casi, M; De Lauro, F; Fabbri, C; Gentili, G; Mattone, V; Sarti, G | 1 |
| Koizumi, M; Kurosawa, G; Kurosawa, Y; Okada, M; Saga, T; Satoh, H; Sudo, H; Sugyo, A; Tsuji, AB | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Bower, GD; Cade, DN; Do, C; Dowling, R; Gibbs, P; Lichtenstein, M; Lipton, L; Price, D; Tapner, MJ; van Hazel, GA | 1 |
| Albert, NL; Bartenstein, P; Boeck, S; Fendler, WP; Heinemann, V; Ilhan, H; Lehner, S; Michl, M; Paprottka, PM | 1 |
| Kim, AY; Pishvaian, MJ; Unger, K; Wang, H | 1 |
| Lewandowski, RJ; Mascarenhas, NB; Mulcahy, MF; Ryu, RK; Salem, R | 1 |
| Buscombe, JR; Cwikla, JB; Jeziorski, KG; Mikolajczak, R; Nasierowska-Guttmejer, A; Pawlak, D; Sankowski, A; Seklecka, N; Stepien, K; Walecki, J | 1 |
| Chang, CH; Gold, DV; Goldenberg, DM; Karacay, H; McBride, WJ; Ragland, DR; Rossi, EA; Sharkey, RM | 1 |
| Agazzi, A; Aricò, D; Bodei, L; De Cicco, C; De Simone, M; Pacifici, M; Paganelli, G; Quarna, J; Sansovini, M; Sierra, ML | 1 |
| Chandra, P; Jacobs, S; Khazai, N; Umpierrez, GE; Yarandi, SS | 1 |
| de Herder, WW; Krenning, EP; Kwekkeboom, DJ | 1 |
| Forrer, F; Giovacchini, G; Müller-Brand, J; Nicolas, G | 1 |
| Goldenberg, DM; Govindan, SV; Karacay, H; Sharkey, RM | 1 |
| Hoffmann, RT; Jakobs, TF; Paprottka, P; Reiser, MF; Trumm, CG | 1 |
| Choyke, PL; Giesel, FL; Haberkorn, U; Haufe, S; Isermann, B; Kauczor, HU; Kratochwil, C; López-Benítez, R; Mier, W | 1 |
| Bertagna, F; Bettinsoli, G; Biasiotto, G; Bosio, G; Dognini, L; Ferrari, C; Ferrari, V; Franco, F; Giubbini, R; Migliorati, E; Minari, C; Rodella, C; Savelli, G; Tomassetti, P; Zaniboni, A | 1 |
| Buziak-Bereza, M; Gilis-Januszewska, A; Hubalewska-Dydejczyk, A; Jabrocka-Hybel, A; Krolicki, L; Kunikowska, J; Matyja, M; Mikolajczak, R; Pach, D; Sowa-Staszczak, A; Stefanska, A; Tomaszuk, M; Trofimiuk, M | 1 |
| Reidy-Lagunes, D; Thornton, R | 1 |
| Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA | 1 |
| Fischbach, J; Gryczyńska, M; Gut, P; Klimowicz, A; Matysiak-Grześ, M; Ruchała, M; Waśko, R | 1 |
| Cardillo, TM; Gold, DV; Modrak, D; Schutsky, K | 1 |
| Cardillo, TM; Gold, DV; Modrak, DE; Schutsky, K | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W | 1 |
| Chen, J; Hinni, K; Maecke, HR; Reubi, JC; Waldherr, C; Waser, B; Zhang, H | 1 |
| Amesur, N; Avril, N; Bienert, M; Carr, BI; Geller, DA; McCook, B; Sheetz, M; Tutor, C | 1 |
| de Jong, M; Esser, JP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R | 1 |
| Bakker, WH; Barone, R; Bouterfa, H; Jamar, F; Krenning, EP; Kvols, LK; Kwekkeboom, DJ; Pauwels, S; Valkema, R | 1 |
| Bushnell, D | 1 |
| Balalla, B; Diamond, T; Ho, KW; Wong, CC | 1 |
| Chen, J; de Jong, M; Ginj, M; Maecke, HR; Reubi, JC; Schmitt, JS; Schulz, S; Waser, B | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
| Abdel-Misih, R; Dignazio, M; Garcia, M; Khatri, J; Neff, R; Petrelli, N; Wilson, P | 1 |
| Bodei, L; Davì, MV; Falconi, M; Ferdeghini, M; Francia, G; Lo Cascio, V; Oliani, C; Paganelli, G; Testoni, M | 1 |
| Albert, R; Briner, U; Bruns, C; Mäcke, HR; Ruser, G; Smith-Jones, PM; Stolz, B | 1 |
| Bakker, WH; Bernard, BF; De Bruin, E; De Jong, M; Krenning, EP; Mäcke, HR; Van Gameren, A; Visser, TJ | 1 |
| Albert, R; Bruns, C; Raulf, F; Smith-Jones, PM; Stolz, B; Weckbecker, G | 1 |
| Angelberger, P; Bischof, C; Gludovacz, D; Hamilton, G; Kaserer, K; Kofler, A; Leimer, M; Pangerl, T; Peck-Radosavljevic, M; Schlangbauer-Wadl, H; Smith-Jones, PM; Traub, T; Virgolini, I | 1 |
| Bernard, HF; Breeman, WA; De Jong, M; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Mäcke, HR; Slooter, GD; Valkema, R; Van Eijck, CH | 1 |
| Chinol, M; Cremonesi, M; Mäcke, HR; Paganelli, G; Zoboli, S | 1 |
| Cardillo, TM; Gold, DV; Ying, Z | 1 |
| Bakker, WH; Bernard, BF; Breeman, WA; de Jong, M; Kooij, PP; Krenning, EP; van Gameren, A; Visser, TJ | 1 |
| Beglinger, C; Christe, M; Eberle, AN; Eisenwiener, K; Froidevaux, S; Heppeler, A; Mäcke, HR; Schmitt, JS; Sumanovski, L | 1 |
| Bakker, WH; Breeman, WA; De Jong, M; Jamar, F; Krenning, EP; Kvols, LK; Kwekkeboom, DJ; Pauwels, S; Smith, C; Valkema, R | 1 |
| Bosslet, K; Bruynck, A; Hermentin, P; Kuhlmann, L; Magerstaedt, M; Schwarz, A; Sedlacek, HH; Seemann, G; Steinstraesser, A | 1 |
| Fowler, JF; Hsieh, JT; Kinsella, TJ; Kubsad, SS; Mehta, MP; Verma, AK | 1 |
9 review(s) available for yttrium radioisotopes and Pancreatic Neoplasms
| Article | Year |
|---|---|
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Topics: Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Receptors, Peptide; Stomach Neoplasms; Yttrium Radioisotopes | 2018 |
Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Embolization, Therapeutic; Humans; Liver Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2022 |
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Topics: Animals; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes | 2011 |
Targeted radiotherapy with radiolabeled somatostatin analogs.
Topics: Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Radiation Injuries; Radioisotopes; Radionuclide Imaging; Radiotherapy; Somatostatin; Yttrium Radioisotopes | 2011 |
Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization).
Topics: Antineoplastic Agents; Breast Neoplasms; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Melanoma; Microspheres; Neuroendocrine Tumors; Pancreatic Neoplasms; Yttrium Radioisotopes | 2011 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes | 2012 |
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
Topics: Animals; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Patient Selection; Pentetic Acid; Peptides, Cyclic; Quality of Life; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Somatostatin; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.
Topics: Clinical Trials as Topic; Humans; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Somatostatin; Yttrium Radioisotopes | 2006 |
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
Topics: Animals; Humans; Indium Radioisotopes; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Rats; Receptors, Somatostatin; Tumor Cells, Cultured; Yttrium Radioisotopes | 2002 |
10 trial(s) available for yttrium radioisotopes and Pancreatic Neoplasms
| Article | Year |
|---|---|
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Yttrium Radioisotopes | 2015 |
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radionuclide Imaging; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |
Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
Topics: Adult; Aged; Chromogranin A; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Retreatment; Survival Rate; Yttrium Radioisotopes | 2012 |
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2012 |
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Topics: Adult; Aged; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Survival Rate; Yttrium Radioisotopes | 2006 |
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Topics: Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes | 1999 |
44 other study(ies) available for yttrium radioisotopes and Pancreatic Neoplasms
| Article | Year |
|---|---|
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.
Topics: Humans; Male; Pancreatic Neoplasms; Prostatic Neoplasms; Quinolines; Sarcoma; Yttrium Radioisotopes | 2022 |
Remarkable regression of inoperable pancreatic grade 3 neuroendocrine neoplasm after radioligand therapy with [177Lu]Lu-DOTATATE and [90Y]Y‑DOTATATE.
Topics: Humans; Pancreatic Neoplasms; Positron-Emission Tomography; Yttrium Radioisotopes | 2023 |
Effectiveness of Liver-Directed Therapy for the Management of Intractable Hypoglycemia in Metastatic Insulinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Embolization, Therapeutic; Female; Humans; Hypoglycemia; Insulinoma; Liver; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2020 |
Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Topics: Animals; Antibodies, Monoclonal; Basigin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Radioimmunotherapy; Yttrium Radioisotopes | 2018 |
Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.
Topics: Animals; Antibodies, Monoclonal; Body Weight; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Integrin alpha6beta4; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Positron-Emission Tomography; Radioimmunotherapy; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2016 |
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Female; Mice; Pancreatic Neoplasms; Positron-Emission Tomography; Thromboplastin; Tissue Distribution; Yttrium Radioisotopes | 2020 |
Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
Topics: Adenocarcinoma; Aged; Disease Progression; Embolization, Therapeutic; Female; Glass; Humans; Male; Microspheres; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Time Factors; Yttrium Radioisotopes | 2020 |
Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Radiopharmaceuticals; Retrospective Studies; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2019 |
Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Digestive System Neoplasms; Embolization, Therapeutic; Female; Humans; Intestinal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiography; Retrospective Studies; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Management of malignant insulinoma.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Diazoxide; Everolimus; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Insulinoma; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Sirolimus; Treatment Outcome; Vasodilator Agents; Yttrium Radioisotopes | 2013 |
Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.
Topics: Female; Humans; Intestinal Neoplasms; Intestine, Small; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
Topics: Aged; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
Topics: Adult; Aged; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Yttrium Radioisotopes | 2014 |
Radioembolization in the treatment of neuroendocrine tumors of the pancreas.
Topics: Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Radiotherapy Dosage; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Liver abscess following radioembolization with yttrium-90 microspheres.
Topics: Fatal Outcome; Female; Humans; Liver Abscess; Microspheres; Middle Aged; Pancreatic Neoplasms; Radiation Injuries; Radiopharmaceuticals; Treatment Outcome; Yttrium Radioisotopes | 2014 |
(90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.
Topics: Aged; Humans; Kidney; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Receptors, Somatostatin; Signal-To-Noise Ratio; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2015 |
Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Immunohistochemistry; Indium Radioisotopes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Radioimmunotherapy; Receptors, Transferrin; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2015 |
Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Disease Progression; Disease-Free Survival; Embolization, Therapeutic; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.
Topics: Aged; Carcinoma, Pancreatic Ductal; Catheter Ablation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Ducts; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Yttrium; Yttrium Radioisotopes | 2016 |
Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis.
Topics: Adenoma, Islet Cell; Angiography; Embolization, Therapeutic; Female; Humans; Liver Abscess; Liver Neoplasms; Microspheres; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2010 |
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Heterocyclic Compounds, 1-Ring; Humans; Mice; Oligopeptides; Pancreatic Neoplasms; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2009 |
Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.
Topics: Adult; Aged; B-Lymphocytes; Colonic Neoplasms; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Lung Neoplasms; Lutetium; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Yttrium Radioisotopes | 2009 |
Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma.
Topics: Embolization, Therapeutic; Female; Humans; Hypoglycemia; Insulinoma; Liver Neoplasms; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Radionuclide Imaging; Yttrium Radioisotopes | 2010 |
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Camptothecin; Cell Line, Tumor; Female; Humans; Immunotoxins; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2011 |
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Statistics as Topic; Thyroid Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Combined octreotide and peptide receptor radionuclide therapy ((90)Y-DOTA-TATE) in case of malignant insulinoma.
Topics: Adult; Antineoplastic Agents, Hormonal; Chemoradiotherapy; Female; Humans; Insulinoma; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radionuclide Imaging; Yttrium Radioisotopes | 2012 |
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Radioimmunotherapy; Time Factors; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental; Organometallic Compounds; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2004 |
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
Topics: Animals; Bombesin; Drug Stability; Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Male; Pancreatic Neoplasms; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Receptors, Bombesin; Tissue Distribution; Yttrium Radioisotopes | 2004 |
90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy.
Topics: Hepatic Artery; Humans; Injections, Intra-Arterial; Insulinoma; Liver Neoplasms; Male; Microspheres; Middle Aged; Pancreatic Neoplasms; Yttrium Radioisotopes | 2006 |
Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
Topics: Animals; Cell Line; Disease Models, Animal; Drug Design; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Molecular Conformation; Neoplasm Transplantation; Octreotide; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Somatostatin; Stereoisomerism; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 2006 |
The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Yttrium Radioisotopes | 2008 |
Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.
Topics: Adrenocorticotropic Hormone; Adult; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cushing Syndrome; Female; Gastrinoma; Humans; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Yttrium Radioisotopes | 2008 |
Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
Topics: Animals; Drug Stability; Half-Life; Humans; Indicators and Reagents; Male; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radioligand Assay; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 1998 |
Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
Topics: Animals; Binding, Competitive; Biological Transport; Carcinoma; Cell Line; Humans; Indium Radioisotopes; Kinetics; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Rats; Receptors, Somatostatin; Temperature; Thyroid Neoplasms; Tumor Cells, Cultured; Yttrium Radioisotopes | 1998 |
The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
Topics: Animals; Humans; Octreotide; Pancreatic Neoplasms; Polymerase Chain Reaction; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Tissue Distribution; Yttrium Radioisotopes | 1998 |
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoid Tumor; Cell Membrane; Colonic Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Pancreatic Neoplasms; Peptides, Cyclic; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Thyroid Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 1999 |
Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
Topics: Animals; Dose-Response Relationship, Radiation; Humans; Indium Radioisotopes; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Yttrium Radioisotopes | 1999 |
Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Female; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Mucins; Neoplasm Transplantation; Pancreatic Neoplasms; Radioimmunotherapy; Survival Analysis; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2001 |
Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
Topics: Animals; Dose-Response Relationship, Radiation; Male; Neoplasm Transplantation; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Yttrium Radioisotopes | 2001 |
Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Neuroendocrine; Cells, Cultured; Female; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Kidney; Mice; Mice, Nude; Mice, SCID; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Yttrium Radioisotopes | 2002 |
Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.
Topics: Animals; Antibodies, Monoclonal; Colonic Neoplasms; Humans; Injections, Intravenous; Mice; Mice, Nude; Pancreatic Neoplasms; Pentetic Acid; Tumor Cells, Cultured; Yttrium Radioisotopes | 1991 |
90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis.
Topics: Animals; Antibodies, Monoclonal; Carcinoma; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Pentetic Acid; Radiotherapy Dosage; Tissue Distribution; Transplantation, Heterologous; Yttrium Radioisotopes | 1990 |